A5087437906- Metabolism and Genetic Disorders
- Chronic Lymphocytic Leukemia Research
- Renal cell carcinoma treatment
- Bladder and Urothelial Cancer Treatments
- Neonatal Health and Biochemistry
- Immunodeficiency and Autoimmune Disorders
- Mitochondrial Function and Pathology
- Peroxisome Proliferator-Activated Receptors
- Amino Acid Enzymes and Metabolism
- Patient Satisfaction in Healthcare
- Peptidase Inhibition and Analysis
- T-cell and B-cell Immunology
- Monoclonal and Polyclonal Antibodies Research
- Heart Failure Treatment and Management
- Lung Cancer Treatments and Mutations
- Acute Myocardial Infarction Research
- Multiple Sclerosis Research Studies
- Lymphoma Diagnosis and Treatment
- Lung Cancer Research Studies
- Cardiac, Anesthesia and Surgical Outcomes
- Cancer Immunotherapy and Biomarkers
- Urinary and Genital Oncology Studies
- Advanced Breast Cancer Therapies
- Emergency and Acute Care Studies
- Health Promotion and Cardiovascular Prevention
University of Liverpool
2020-2023
The Christie NHS Foundation Trust
2018
Recurrence is common after neoadjuvant chemotherapy and radical treatment for muscle-invasive bladder cancer. We investigated the effect of adding nintedanib to on response survival in cancer.NEOBLADE was a parallel-arm, double-blind, randomised, placebo-controlled, phase 2 trial gemcitabine cisplatin with or placebo locally advanced Patients aged 18 years older, an Eastern Cooperative Oncology Group performance status 0-1, were recruited from 15 hospitals UK. randomly assigned (1:1) using...
Abstract Background Outcomes from studies employing nitisinone 10 mg and 2 in alkaptonuria were compared. Patients methods Sixty‐nine patients each of the (10 daily) controls suitability (SONIA 2), as well 37 23 (2 control cohorts at National Alkaptonuria Centre (NAC), respectively, followed up for 4 years. Severity (AKU) was assessed by AKU Score Index (AKUSSI). 24‐h urine homogentisic acid (uHGA 24 ), serum HGA (sHGA), tyrosine (sTYR) (sNIT) also analysed time point. Dietetic support used...
438 Background: Neo-adjuvant chemotherapy Improves overall survival in patients with MIBC. Nintedanib is an orally available, potent, small molecule, triple kinase inhibitor the potential to further benefit patient prognosis. Methods: NEO-BLADE was designed as a randomised, placebo controlled phase II study (n=120) compare addition of nintedanib (N) (150mg/200mg BD) combination Gemcitabine (G) and Cisplatin (C). The powered (80%, alpha=15% [one sided]) detect improvement histological...
Although changes in the tyrosine pathway during nitisinone therapy are known, a complete characterization of induced tyrosinaemia is lacking to improve disease management.Our research aims were addressed by 24-h blood sampling. 40 patients with alkaptonuria (AKU), treated 0, 1, 2, 4 and 8 mg daily (n = 8), studied over four weeks. Serum homogentisic acid (sHGA), (sTYR), phenylalanine (sPHE), hydroxyphenylpyruvate (sHPPA), hydroxyphenyllactate (sHPLA) (sNIT) measured at baseline after...
Ochronotic spondyloarthropathy represents one of the main clinical manifestations alkaptonuria (AKU); however, prospective data and description effect nitisinone treatment are lacking. Patients with AKU aged 25 years or older were randomly assigned to receive either oral 10 mg/day (N=69) no (N=69). Spine radiographs recorded yearly at baseline, 12, 24, 36 48 months, images scored for presence intervertebral space narrowing, soft tissue calcifications, vacuum phenomena,...
Nitisinone (NTBC) was recently approved to treat alkaptonuria (AKU), but there is no information on its impact oxidative stress and inflammation, which are observed in AKU. Therefore, serum samples collected during the clinical studies SONIA1 (40 AKU patients) SONIA2 (138 were tested for Serum Amyloid A (SAA), CRP IL-8 by ELISA; Advanced Oxidation Protein Products (AOPP) spectrophotometry; protein carbonyls Western blot. Our results show that NTBC had significant effects markers except a...
Chest pain (CP) is one of the most frequent presentations to emergency department (ED), a large proportion which non-cardiac chest (NCCP). Repeat attendances ED are common and impose considerable burden overstretched departments. Our aim was determine drivers for repeat using NCCP as primary cause index presentation. This retrospective cohort study 1066 consecutive with major urban hospital in North England. Index Multiple Deprivation (IMD), postcode-derived validated deprivation, computed....
Abstract Introduction Repeat attendances with noncardiac chest pain (NCCP) to emergency room (ER) are frequent..Our aim was analyse predictors of repeat presentations ER in patients NCCP. Methods We prospectively enrolled 1066 consecutive NCCP a major urban hospital ER. Index multiple deprivation (IMR) computed. Charlson comorbidity (CCM) index determined. presentation any national determined by linked database (pop. 53.5m). Results Median age 43 (IQR 28, 59), 50.8% were male. 63% current or...